| A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment (NCT07392060) | Shanghai Jiatan Pharmatech Co., Ltd | 2026-02-28 |
| Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults (NCT06701136) | Shanghai Jiatan Pharmatech Co., Ltd | 2025-05-12 |
| Pharmacokinetic Study of Sudapyridine（WX-081）in Healthy Chinese Subjects (NCT06701110) | Shanghai Jiatan Pharmatech Co., Ltd | 2024-09-04 |
| A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations (NCT06124963) | Shanghai Jiatan Pharmatech Co., Ltd | 2023-08-25 |
| A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors (NCT06117566) | Shanghai Jiatan Pharmatech Co., Ltd | 2022-11-18 |
| A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients (NCT05824871) | Shanghai Jiatan Pharmatech Co., Ltd | 2022-09-02 |
| A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations (NCT06132932) | Shanghai Jiatan Pharmatech Co., Ltd | 2021-06-03 |
| A Study of WX390 in Patients With Advanced Solid Tumors (NCT06117540) | Shanghai Jiatan Pharmatech Co., Ltd | 2021-05-11 |
| Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081 (NCT04608955) | Shanghai Jiatan Pharmatech Co., Ltd | 2020-10-16 |
| Sudapyridine (WX-081) in Healthy Volunteers (NCT06117514) | Shanghai Jiatan Pharmatech Co., Ltd | 2019-02-13 |
| A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma (NCT03730142) | Shanghai Jiatan Pharmatech Co., Ltd | 2018-10-25 |